(Q35641366)

9 August 2017

1 reference

title

Gemcitabine-induced severe pulmonary toxicity (English)

1 reference

9 August 2017

Fabrice Barlési

1 reference

9 August 2017

Patrick Villani

1 reference

9 August 2017

Christophe Doddoli

1 reference

9 August 2017

Céline Gimenez

1 reference

9 August 2017

Jean-Pierre Kleisbauer

1 reference

9 August 2017

publication date

1 February 2004

1 reference

Fundamental and Clinical Pharmacology

9 August 2017

published in

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

85-91

1 reference

Phase II study of gemcitabine in patients with advanced pancreatic cancer

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

A report on serious pulmonary toxicity associated with gemcitabine-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Fatal pulmonary toxicity resulting from treatment with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Diffuse alveolar damage in a patient treated with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Severe non-haematological toxicity after treatment with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Severe acute lung injury induced by gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Gemcitabine-induced pulmonary toxicity: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Severe pulmonary toxicity in a patient treated with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Bleomycin-induced pneumonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Radiation recall reaction following gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

The "recall effect" in radiotherapy: is subeffective, reparable damage involved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Severe interstitial pneumonitis associated with docetaxel administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Gemcitabine-induced systemic capillary leak syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

Fatal pulmonary veno-occlusive disease possibly related to gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0767-3981.2003.00206.X

10.1046/J.0767-3981.2003.00206.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference